

Gonzalo Recondo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2455337/publications.pdf>

Version: 2024-02-01

45
papers

1,494
citations

516710

16
h-index

361022

35
g-index

45
all docs

45
docs citations

45
times ranked

2196
citing authors

#	ARTICLE	IF	CITATIONS
1	Osimertinib and chemotherapy combination to treat brain metastasis flare and osimertinib resistance by EGFR C797S. <i>Journal of Chemotherapy</i> , 2023, 35, 168-172.	1.5	1
2	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. <i>Journal of Thoracic Oncology</i> , 2022, 17, 399-410.	1.1	151
3	p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics. <i>Translational Oncology</i> , 2022, 15, 101276.	3.7	11
4	Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FREESTON-CLICaP). <i>Clinical Lung Cancer</i> , 2022, 23, 522-531.	2.6	5
5	Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. <i>JAMA Oncology</i> , 2022, 8, 1160.	7.1	117
6	Outcomes of patients with non-small cell lung cancer and poor performance status treated with immune checkpoint inhibitors in the real-world setting. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1057-1064.	2.2	2
7	When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. <i>Oncology and Therapy</i> , 2021, 9, 89-110.	2.6	36
8	Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC). , 2021, 9, e001504.		72
9	EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP). <i>JCO Precision Oncology</i> , 2021, 5, 839-848.	3.0	3
10	Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9018-9018.	1.6	4
11	Therapeutic strategies to overcome ALK resistance in lung cancer. , 2021, , 123-139.		0
12	A New Pretreatment Mesothelioma Risk Score: Integrating Clinical and Molecular Factors for Predicting Outcomes in Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1782-1784.	1.1	1
13	Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 787585.	2.8	20
14	Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 242-255.	7.0	114
15	Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). <i>Thoracic Cancer</i> , 2020, 11, 2552-2560.	1.9	12
16	Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy. <i>Npj Precision Oncology</i> , 2020, 4, 27.	5.4	16
17	Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). <i>Frontiers in Oncology</i> , 2020, 10, 588932.	2.8	4
18	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4135-4142.	7.0	95

#	ARTICLE	IF	CITATIONS
19	Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America. <i>JCO Global Oncology</i> , 2020, 6, 752-760.	1.8	11
20	Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. <i>Annals of Oncology</i> , 2020, 31, 807-814.	1.2	65
21	Targeting MET Dysregulation in Cancer. <i>Cancer Discovery</i> , 2020, 10, 922-934.	9.4	94
22	Oncogenic Fusions May Be Frequently Present at Resistance of EGFR Tyrosine Kinase Inhibitors in Patients With NSCLC: A Brief Report. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100023.	1.1	11
23	High Prevalence of Somatic Oncogenic Driver Alterations in Patients With NSCLC and Li-Fraumeni Syndrome. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1232-1239.	1.1	29
24	Immunotherapy combinations for the treatment of patients with solid tumors. <i>Future Oncology</i> , 2020, 16, 1715-1736.	2.4	6
25	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14 Mutant NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2615-2625.	7.0	129
26	Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection. <i>Lung Cancer</i> , 2020, 145, 181-185.	2.0	36
27	Clinical Relevance of an Amplicon-Based Liquid Biopsy for Detecting ALK and ROS1 Fusion and Resistance Mutations in Patients With Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 272-282.	3.0	36
28	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100074.	1.1	10
29	Clinical characteristics, genomic features, and recurrence risk of early-stage MET exon 14 mutant non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2020, 38, 9042-9042.	1.6	1
30	Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status. <i>Journal of Clinical Oncology</i> , 2020, 38, e151113-e151113.	1.6	7
31	The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 162-174.	0.7	38
32	Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. <i>Future Oncology</i> , 2020, 16, 1659-1664.	2.4	2
33	Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer. <i>JTO Clinical and Research Reports</i> , 2020, , 100092.	1.1	1
34	Access of patients with breast and lung cancer to chemotherapy treatment in public and private hospitals in the city of Buenos Aires. <i>International Journal for Quality in Health Care</i> , 2019, 31, 682-690.	1.8	4
35	DNA damage response gene alterations are associated with high tumor mutational burden and clinical benefit from programmed death 1 axis inhibition in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 9077-9077.	1.6	2
36	Impact of KRAS allele subtypes and concurrent genomic alterations on clinical outcomes to programmed death 1 axis blockade in non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 9082-9082.	1.6	4

#	ARTICLE	IF	CITATIONS
37	Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 694-708.	27.6	255
38	Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 87-92.	0.8	3
39	Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine. <i>Cancer Management and Research</i> , 2016, 8, 57.	1.9	20
40	What is the Current Role of Immunotherapy for Colon Cancer?. <i>Reviews on Recent Clinical Trials</i> , 2016, 11, 93-98.	0.8	4
41	Spindle epithelial tumor with thymus-like differentiation: A case report and comprehensive review of the literature and treatment options. <i>Head and Neck</i> , 2015, 37, 746-754.	2.0	21
42	Anti-Hormonal Therapies for Premenopausal Patients – What did we Learn from the TEXT/SOFT Trials?. <i>Reviews on Recent Clinical Trials</i> , 2015, 10, 90-100.	0.8	3
43	Advances and new perspectives in the treatment of metastatic colon cancer. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 211.	2.0	25
44	Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. <i>World Journal of Clinical Oncology</i> , 2014, 5, 440.	2.3	11
45	Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib. <i>Precision Cancer Medicine</i> , 0, 4, 28-28.	1.8	2